Two New Drugs Approved for Non–Small Cell Lung Cancer

The Food and Drug Administration (FDA) has approved capmatinib (Tabrecta) for the treatment of metastatic non–small cell lung cancer in adults whose tumors have a mutation leading to mesenchymal-epithelial transition exon 14 skipping.Nurses should monitor patients for serious adverse effects such as interstitial lung disease/pneumonitis, hepatotoxicity, pancreatic toxicity, photosensitivity, and embryo–fetal toxicity.The FDA has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of unresectable or metastatic non–small cell lung cancer in adults whose tumors have activating human epidermal growth factor receptor 2 mutations and who have received a prior systemic therapy.Enhertu carries a boxed warning regarding the risk of interstitial lung disease and embryo–fetal toxicity.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research